'Rising costs mean difficult decisions'
On Wednesday, the government announced the release of £25 million for hospices across England, but this is reserved for facility upgrades and refurbishments only.
Dorothy House Hospice Care, covering Bath and North East Somerset, is set to receive £298,000 of this funding and must spend it by the end of March.
Facing a "significant rise" in demand and costs, hospices across the country have been rallying for a more sustainable, long-term funding solution for the sector.
Stephen Kinnock, the minister for care, said the money would help "transform hospice facilities" across England.
"Hospices provide invaluable care and support when people need it most and this funding boost will ensure they are able to continue delivering exceptional care in better, modernised facilities," he said.
However, the cash is reserved for purchasing new medical equipment, improving gardens, refurbishing buildings, upgrading technology and modernising facilities.
Penny Agent, chief operating officer for Dorothy House, said unless it received support with staffing costs, it would have no choice but to cut back on services.
"We are really appreciative of this recent funding, however it is ringfenced, and we can only really use it on estate or capital use," Ms Agent said.
"It's all well and good having a very pretty estate, but if you can't actually pay the staff who provide the care to our patients, it all crumbles."
It currently costs Dorothy House £19 million per year to provide its services. Just 20% of this funding comes from government, with donations providing the rest.
"The funding we receive has not kept pace with the increase in costs," Ms Agent explained.
"Unless we get additional and appropriate funding, we're going to have to make some really difficult decisions around how we deliver our services."
Susan Hamilton, CEO of St Peter's Hospice based in Bristol, said the charity supported around 3,000 patients per year, but that number was rapidly rising.
"We welcome these ongoing discussions that the sector is having with government to achieve that sustainable solution," she said.
"But this is only money for this year, the question is, what happens after that?"
Follow BBC Somerset on Facebook and X. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Zipline to run through city's iconic crescent
Hospice must find £400k to cover rise in NI costs
Hospices in England to receive £100m funding boost
Dorothy House
St Peter's Hospice
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Paclitaxel Balloon Improves Complex Stent Care
TOPLINE: In patients with multilayer in-stent restenosis (ISR), treatment with a paclitaxel-coated balloon reduced target lesion failure (TLF) at 1 year to 23.8% compared with 40% with an uncoated balloon. The approach showed consistent benefits in patients with multilayer and single-layer ISR, with a greater absolute reduction in risk among multilayer cases. METHODOLOGY: A total of 600 patients with ISR were randomized in a 2:1 ratio to receive either a paclitaxel-coated or uncoated balloon treatment at 40 clinical sites in the US. Participants had ISR with a reference vessel diameter between 2 mm and 4 mm, and lesion length < 26 mm, with target stenosis > 50% for symptomatic or > 70% for asymptomatic cases before predilation. Randomization was stratified by multilayer vs single-layer ISR, and by the study's enrollment center, with 258 patients (44%) presenting with multilayer ISR. The primary endpoints was failure of the target lesion 1 year after treatment, an outcome which consisted of ischemia-driven target lesion revascularization, target vessel-related myocardial infarction, or cardiac death. TAKEAWAY: Among patients with multilayer ISR, failure of the target lesion was significantly less likely with a paclitaxel-coated balloon than with an uncoated device (23.8% vs 40%; hazard ratio, 0.55; 95% CI, 0.34-0.87; P = .01). Rates of revascularization of the target lesion were lower with a paclitaxel-coated balloon in cases of multilayer ISR (17.4% vs 37.8%; P = .0003), as were rates of target vessel-related myocardial infarction (5.9% vs 17.2%; P = .005). Patients with multilayer ISR experienced higher overall rates of TLF than those with single-layer ISR (29% vs 15.7%; P < .0001). Six cases of stent thrombosis occurred in the multilayer ISR group treated with uncoated balloons, with no cases reported in the group who received paclitaxel-coated balloons. IN PRACTICE: 'The treatment of multilayer ISR represents a unique clinical challenge for practicing clinicians. The incidence of recurrent ISR following PCI [percutaneous coronary intervention] is relatively high in this group of patients, and finding optimal solutions can be challenging because of the presence of multiple layers of existing stents,' the researchers wrote. 'Treatment with the paclitaxel-coated balloon led to greater absolute risk reduction in 1-year TLF among patients with multilayer ISR compared with an uncoated balloon,' they added. 'An important takeaway from this AGENT IDE subgroup analysis is the need for a lifetime management strategy in patients with ISR undergoing' PCI, Roxana Mehran, MD, of the Mount Sinai Fuster Heart Hospital, in New York City, and her colleagues, wrote in an editorial accompanying the journal article. The findings support the use of drug-coated balloons 'as a treatment option in high-risk patients with multilayer ISR, offering a chance to improve its otherwise poor prognosis. At the same time, the overall unfavorable outcomes observed in this condition highlight the importance of selecting the optimal strategy at the first ISR occurrence,' they added. SOURCE: This study was led by Ajay J. Kirtane, MD, SM, of Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation in New York City. It was published online on August 11, 2025, in Journal of the American College of Cardiology. LIMITATIONS: According to the authors, lesion preparation in this study was relatively conservative, with specialty balloons used in < 40% of cases. The researchers noted that more aggressive, mechanism-driven lesion preparation could have potentially further optimized outcomes, particularly in patients with complex multilayer disease. Additionally, intravascular lithotripsy and stent ablation, which are potential strategies for ISR, were not explored in the study. DISCLOSURES: Boston Scientific Corporation provided funding for the study. Kirtane received institutional funding to Columbia University and/or Cardiovascular Research Foundation from multiple organizations including Medtronic, Boston Scientific, Abbott Vascular, Amgen, CathWorks, Concept Medical, Philips, ReCor Medical, Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, SoniVie, and Shockwave Medical. He also holds equity options in Bolt Medical and Airiver. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
23-07-2025
- Yahoo
Hospices need long-term funding plan, minister says
Financially struggling hospices need a long-term funding plan rather than "sticking plaster" solutions, a government health minister has said. Labour Minister of State for the Department of Health and Social Care Stephen Kinnock last week announced £75 million to be shared by 170 hospices across the country. Unlike the NHS, hospices are not fully funded by the state and rely on charity contributions for about two thirds of their funding, with the sector reporting an estimated shortfall of £60m last financial year. Speaking at Wigan & Leigh Hospice in Greater Manchester, which received £500,000 from the funding pool, Kinnock said the government needed to cover a bigger portion of the cost. "We do warmly welcome the way that people step up and get involved in supporting their local hospice, but I absolutely recognise that we, the Department for Health and Social Care, we need to step up and do our bit," he said. The £75 million is in addition to a £25 million package the government distributed in February. Hospices in the north west of England provide end-of-life and palliative care for some 23,000 people in the region, with demand and costs continuing to rise. Geoff Crook, 68, had been receiving care at Wigan & Leigh Hospice earlier this month alongside his wife Margaret, allowing him to be by her side for her final moments. "I don't think we would have been able to cope if we hadn't had anything like this, I really don't" he said. Wigan & Leigh Hospice chief executive Jo Carby said the £500,000 would be used to fix the building's leaking roof and to put in a new heating system and memory garden. But she said it was "not enough" and that hospices needed a longer-term solution. "Everyone's struggling for money essentially in our borough and it is unfair for us to be asking the people of Wigan to be spending more of their money when they already have less to spend in order to keep the hospice going," she said. Kinnock said the government was currently negotiating how much funding would be allocated to palliative and end-of-life care in its three-year-spending review settlement. He said: "As soon as we have that I want to see that long-term plan to take us at least through to the end of this parliament. Kinnock said the government was determined to find "long-term solutions". "I have made it very clear to my team of officials in [the Department] that I don't want another last-minute scramble at the end of the financial year to, with a sticking plaster, solve a problem for the short term," he said. Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230. More on this story Campaigners warn NHS 'cannot afford hospice cuts' Hospice fears pre-Christmas funding plans shelved Campaigner takes hospice petition to Downing Street Hospices facing funding crisis Related internet links Department of Health & Social Care
Yahoo
11-07-2025
- Yahoo
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
New report adds to growing evidence of iNKT cell therapy's potential in solid tumors NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature's Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK's allogeneic iNKT cell therapy. Complete remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and multiple ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT) The publication, titled 'Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,' presents a patient case from MiNK's clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy—including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD). 'This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers,' said Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners. 'We observed a remarkable response in a patient who had exhausted standard and experimental treatments, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.' Durable Responses & Immune Activation in Solid Tumors with Allo-iNKT Therapy These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors. At the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Notably, extended survival beyond 12 months was observed in several patients—an outcome rarely seen in this setting. These clinical observations were further reinforced in a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab. Together, these data highlight the potential of agenT-797 to reshape the tumor microenvironment and deliver durable clinical activity, even in heavily pretreated, immunotherapy-resistant cancers. The ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional readouts expected in upcoming months. You can access the full publication here. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company advancing a new class of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. The company's lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable highly specific immune targeting across tumor and tissue types. With a scalable manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to delivering accessible, durable, and broadly applicable immune reconstitution therapies. For more information, visit or follow us on X @MiNK_iNKT. Information important to investors is routinely posted to our website and social media channels. About AgenT-797 AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as 'master regulators,' combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al., AACR IO 2024; Oncogene, 2024), as well as reduce inflammation in critically ill patients with severe respiratory pathology (Nature Communications, 2024). Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. CONTACT: Investor Contact 917-362-1370 investor@ Media Contact 781-674-4428 communications@
